See more : Zhongguancun Science-Tech Leasing Co., Ltd. (1601.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Blue Water Vaccines, Inc. (BWV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Blue Water Vaccines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Taiwan Fu Hsing Industrial Co.,Ltd. (9924.TW) Income Statement Analysis – Financial Results
- Demand Brands, Inc. (DMAN) Income Statement Analysis – Financial Results
- GGL Resources Corp. (GGLXF) Income Statement Analysis – Financial Results
- Greencoat Renewables PLC (GRP.L) Income Statement Analysis – Financial Results
- Telecomunicações Brasileiras S.A. – Telebras (TELB4.SA) Income Statement Analysis – Financial Results
Blue Water Vaccines, Inc. (BWV)
About Blue Water Vaccines, Inc.
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.13M | 1.33M | 524.91K | 60.17K |
| General & Administrative | 9.35M | 2.09M | 1.10M | 820.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.35M | 2.09M | 1.10M | 820.06K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 3.42M | 1.62M | 880.23K |
| Cost & Expenses | 13.48M | 3.42M | 1.62M | 880.23K |
| Interest Income | 0.00 | 0.00 | 22.60K | 58.32K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -61.41K | 4.89K | 3.06K | 573.00 |
| EBITDA | -13.48M | -3.41M | -1.62M | -879.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -3.42M | -1.62M | -880.23K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 61.41K | 0.00 | 22.60K | 58.32K |
| Income Before Tax | -13.42M | -3.42M | -1.60M | -821.92K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -129.57K | 0.00 | -22.60K | -58.32K |
| Net Income | -13.29M | -3.42M | -1.58M | -763.60K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -0.31 | -0.14 | -0.07 |
| EPS Diluted | -1.08 | -0.31 | -0.14 | -0.07 |
| Weighted Avg Shares Out | 12.27M | 10.91M | 11.05M | 11.05M |
| Weighted Avg Shares Out (Dil) | 12.27M | 10.91M | 11.05M | 11.05M |
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer, Dr. Neil Campbell.
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
Transaction will Advance Company's Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team Transaction will Advance Company's Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with...
Blue Water Biotech Issues Letter to Shareholders
CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer Dr. Neil Campbell.
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and...
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
CINCINNATI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical company spanning multiple sectors, today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of...
Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), today announced the closing of its previously announced exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at...
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the “Company”) (Nasdaq: BWV), today announced it has entered into a definitive agreement for the exercise of certain existing warrants to purchase 2,486,214 shares of its...
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializing transformational therapies to address significant health challenges globally, today announced an agreement...
Source: https://incomestatements.info
Category: Stock Reports